1 / 40

Breast Cancer Screening

Breast Cancer Screening Eve Espey, M.D. University of New Mexico Objectives To explain the epidemiology of breast cancer among US women To understand screening modalities and current breast cancer screening recommendations To discuss strategies to reduce risk of developing breast cancer

omer
Download Presentation

Breast Cancer Screening

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Breast Cancer Screening Eve Espey, M.D. University of New Mexico

  2. Objectives • To explain the epidemiology of breast cancer among US women • To understand screening modalities and current breast cancer screening recommendations • To discuss strategies to reduce risk of developing breast cancer

  3. Epidemiology of Breast Cancer • 2003: 211,300 new cases of breast cancer and 39,800 deaths • 32% of all newly diagnosed cancers in women are cancers of the breast • Most common cancer diagnosed in women • Most feared health condition by women

  4. Leading Sites of Cancer Incidence and Death in Women (1997 Estimates) CANCER CANCER RANK INCIDENCE DEATHS 1 Breast Lung 192,200 66,000 2 Lung Breast 79,800 40,200 3 Colon/Rectum Colon/Rectum 64,800 27,900 4 Corpus Uteri Ovary 34,900 14,200

  5. Selected Cancer Statistics by Ethnicity

  6. New Mexico Breast Cancer Data

  7. Cancer Mortality Rate Ratio for Females, 1994-98, AI/AN Compared to U.S. All Races All Sites Lung Colon/Rect. Ill Def/Unk. Breast Stomach Liver Pancreas Kidney Ovary Esophagus Cervix Gallbladder .5 .75 1 1.5 2 *AI/AN rate statistically different from US All Races death rates

  8. Breast Cancer Mortality RatesFemales, 1994-98 All IHS (14.1) * All US (24.2) Rate per 100,000 per year, adjusted to 1970 U.S. population Figure 26 ** Denotes a rate significantly higher (* lower) than the U.S. rate.

  9. Risk Factors for Breast Cancer • Female gender • Age over 50

  10. Age

  11. Putting Breast Cancer Risk in Perspective • The “1 in 9” statistic • Cohort of 1000 women • By age 85: • 33 dead from breast cancer • 99 will have diagnosis of breast ca • 203 dead from CV disease

  12. Putting Breast Cancer Risk in Perspective • 1 woman in 9 develops breast cancer • That woman has a 50% chance of being diagnosed after age 65 • That woman has a 60% chance of surviving breast cancer and dying of another cause

  13. Fear of Breast Cancer • Survey of 1000 women age 45-64 • Condition they feared most: • Breast cancer: 61% • Cardiovascular disease: 9%

  14. Other Major Risk Factors • Family History • 1st degree relative • Premenopausal • Bilateral cancer • Personal History • Breast cancer • Carcinoma in situ • Atypical hyperplasia

  15. Minor Risk Factors • Late age at first pregnancy • Nulliparity • High socioeconomic status • Exposure to high dose radiation • Hyperplasia on breast biopsy

  16. Risk factors for BRCA 1 and BRCA 2 • Breast and ovarian cancer • 2 or more relatives < 50 with breast cancer • Male breast cancer • > or = 1 relative < 50 with breast cancer + Ashkenazi Jew • Ovarian cancer + Ashkenazi Jew

  17. Breast cancer and HRT • 5 years of ERT does not increase risk • 5 years of HRT increases risk by 26%

  18. Unproven Risk Factors • Oral contraceptives • Obesity • High fat diet

  19. Breast Cancer Screening • Breast self exam (BSE) • Clinical breast exam (CBE) • Mammography

  20. USPSTF and Canadian TFPHCRating of evaluations • A: Strong recommendation to include the service • B: Recommendation to include the service • C: No recommendation either for or against • D: Recommendation against routine provision of the service • I: Evidence insufficient

  21. Breast self exam:Canadian Task force on Prevention • Fair evidence of no benefit • Good evidence of harm • Overall fair evidence that routine teaching of BSE should be excluded from the annual exam • D recommendation June, 2001

  22. USPSTF: 2002Should we recommend BSE? BSE: insufficient evidence to recommend for or against • “I” recommendation

  23. Studies evaluating BSE • 2 RCTs, 1 quasi RCT, 3 case-control studies • No difference in breast cancer mortality • No difference in stage of cancer at diagnosis • More provider visits: 8% vs. 4% • More benign biopsies

  24. ACOG Practice Bulletin: Breast cancer screening April, 2003 • Despite a lack of definitive data for or against breast self-examination, breast self-examination has the potential to detect palpable breast cancer and can be recommended.

  25. Costs of BSE • $700 per competent frequent self-examiner • Opportunity cost: limited time for counseling • Anxiety, worry, depression

  26. Should we recommend mammography?

  27. Disadvantages of Screening Age 40-49 1/3 of women undergoing annual screening mammography between 40-49 will have an abnormal mammo requiring: • Further imaging studies • FNA or core biopsy • Excisional biopsy

  28. Does mammography work? • 2001: Cochrane review by Olsen and Gotzsche found no reduction in mortality • 5 of 8 trials seriously flawed • 3 “sound” trials showed no benefit • Methodological flaws negate findings of benefit

  29. Does mammography work? • 2002: USPSTF reviewed Cochrane findings • Only 1 trial seriously flawed • Flaws “problematic” but unlikely to negate findings of benefit • Downgraded recommendation (A to B) but included all women > 40

  30. Mortality is declining • 1990-1999: breast cancer mortality has decreased by 17%

  31. New screening technologies • Full-field digital mammography • Computer-assisted detection • MRI • Ultrasound

  32. Screening Mammogram ReportsBirads • Birads 0: Incomplete study • Birads 1: Normal, routine follow-up • Birads 2: Benign finding, routine follow-up • Birads 3: Probably benign finding, 6 month follow-up • Birads 4: Suspicious finding, consider biopsy • Birads 5: Highly suspicious, biopsy required

  33. Limitations of Mammography • Palpable masses must be evaluated despite NEGATIVE results

  34. Gail Model • http://bcra.nci.nih.gov/brc/ • Calculates 5 year risk of developing breast cancer • Age • Age at menarche • # of breast biopsies • Age at first live birth • Number of first degree relatives with breast cancer

  35. Reducing the risk of breast cancer • Chemoprevention • Tamoxifen and raloxifene: • 38% decrease in breast cancer incidence?? Reduction in mortality • Tamoxifen • Endometrial cancer, DVT • Raloxifene • DVT

  36. Chemoprevention • NSAIDs?? • 2 or more tabs/wk of ASA/ibuprofen led to a 21% decrease in breast cancer risk in the WHI trial

  37. Reducing the risk of breast cancer • Prophylactic surgery • Bilateral mastectomy • Reduces risk by 90% • Bilateral oophorectomy • Lifestyle • Reduction in fat intake, exercise, weight loss, reduction in alcohol

  38. Summary • Take down your shower card for BSE • Encourage mammography • Work up palpable masses • Don’t worry quite so much…

More Related